{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:48:06Z","timestamp":1781801286622,"version":"3.54.5"},"reference-count":11,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1004979","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:22:55Z","timestamp":1773163375000},"page":"e1004979","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-4628","authenticated-orcid":true,"given":"David B.","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Simanonok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-3096","authenticated-orcid":true,"given":"Douglas A.","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"4","key":"pmed.1004979.ref001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"DM Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"pmed.1004979.ref002","first-page":"1981","article-title":"KEYNOTE-522 Investigators.","volume":"391","author":"P Schmid","year":"2024","journal-title":"N Engl J Med."},{"issue":"2","key":"pmed.1004979.ref003","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial","volume":"31","author":"F Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"pmed.1004979.ref004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"S Loi","year":"2025","journal-title":"Nat Med"},{"key":"pmed.1004979.ref005","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-RF3-05","article-title":"Abstract RF3-05: A phase 2 study of neoadjuvant HER2-targeted therapy +\/- immunotherapy with pembrolizumab (neoHIP).","volume":"31","author":"H McArthur","year":"2025","journal-title":"Clin Cancer Res."},{"issue":"2","key":"pmed.1004979.ref006","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"R Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"pmed.1004979.ref007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-020-0156-0","article-title":"Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer","volume":"6","author":"Z Kos","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"pmed.1004979.ref008","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"HR Ali","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"pmed.1004979.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004647","article-title":"Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER- breast cancer: a retrospective cohort study","volume":"22","author":"AE Walker","year":"2025","journal-title":"PLoS Med"},{"issue":"9","key":"pmed.1004979.ref010","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/cancers14092148","article-title":"Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression","volume":"14","author":"DJ Fassler","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"pmed.1004979.ref011","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/path.6165","article-title":"Spatial analyses of immune cell infiltration in cancer: current methods and future directions: a report of the International Immuno\u2010Oncology Biomarker Working Group on Breast Cancer","volume":"260","author":"DB Page","year":"2023","journal-title":"J Pathol"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:22:57Z","timestamp":1773163377000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004979","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}